Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.